Sign in
Taking people in United StatesPhase 4

Tests dapagliflozin after delivery in people with high-blood-pressure pregnancies

Tests dapagliflozin or a placebo for heart risk after pregnancy high blood pressure.

Key facts

Who runs it
University of Michigan
Where
Ann Arbor, United StatesSee the site
Trial code
Registry title
A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)
Status
Recruiting
Phase
Phase 4
People taking part
200 people, planned
Started
2 Mar 2025
Expected to end
Aug 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Placebo
  • Dapagliflozin 10mg Tab
Record updated
4 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women who had a pregnancy with high blood pressure and are at high risk of heart problems after delivery. They will take dapagliflozin or a placebo for six months.

Age
18 years or older
Sex
Women only
Disease stage
High blood pressure in pregnancy: chronic or essential hypertension, gestational hypertension, pre-eclampsia, superimposed pre-eclampsia or eclampsia. Delivery at or after 23 and 0/7 weeks of pregnancy.
Earlier treatment
Taking a blood pressure medicine when admitted counts as one way to qualify. No other prior treatment is asked for.
Biomarker or test result
Two or more blood pressure readings of 160/110 mmHg or higher, at least 60 minutes apart. If this is not met, a BNP of 100 pg/ml or higher within 12 hours of delivery can be used instead.

Main reasons for not taking part

  • Does not speak English
  • Still pregnant
  • Wants to become pregnant within 8 months after delivery
  • Plans to breastfeed after enrolment
  • BNP of 1000 pg/ml or higher within 12 hours of delivery

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Admitted for delivery at the University of Michigan (UM) Labor and Delivery (L\&D) unit or enrolled in the UM postpartum blood pressure monitoring program following a delivery at the UM L\&D unit
  • Determined to be at least 23 and 0/7 weeks of gestation based on a clinically acceptable dating method (can be a single or multifetal gestation with or without the presence of fetal anomalies) at the time of delivery
  • Consents to participation and must understand/read/speak English with the ability to understand and willingness to sign a written informed consent in English
  • Diagnosed with a hypertensive pregnancy by either of the following criteria:; Taking an antihypertensive medication for the diagnosis of chronic or essential hypertension at the time of admission; Hypertension, chronic hypertension, or essential hypertension must be present in the prospective participant's medical record; Antihypertensive" can be any medication taken for the purpose of blood pressure control per the medical record; A documented hypertensive disorder of pregnancy (gestational hypertension, preeclampsia without severe features, preeclampsia with severe features, superimposed preeclampsia, or eclampsia) prior to delivery
  • Eligible participants must report a planned contraceptive method as part of the consent process, to be noted on their consent document
  • Has two or more blood pressures ≥160/110 Millimeters of mercury (mmHg) at least 60 minutes apart; If an admitted patient does not meet this blood pressure criterion but is otherwise eligible, participants can consent to have a BNP drawn within 12 hours of delivery as an alternative measure of cardiovascular risk (if the brain natriuretic peptide (BNP) is ≥100 Picograms per milliliter (pg/ml), participants are eligible to participate)

Who cannot take part

  • Non-English speaking
  • Ongoing pregnancy
  • Stated desire to become pregnant within 8 months post-delivery
  • Intention to breastfeed after enrollment
  • BNP ≥1000 pg/ml within 12 hours of delivery, clinical team to be notified of result
  • Comorbidities that may affect cardiovascular risk assessment (per protocol)
  • Contraindication to dapagliflozin (per protocol)

Where in United States

  • University of MichiganAnn Arbor, United StatesContact: Levi AndersonTaking people

About the trial

What the trial wants to find out

This trial is a pilot-scale, single institution randomized, placebo-controlled trial to assess the feasibility, acceptability, and efficacy of administering dapagliflozin for cardiovascular risk reduction in the postpartum period. The target population is patients at high risk of adverse cardiovascular outcomes within five years post-delivery.

Read full original descriptionShow less

Eligible participants will be randomized to receive either: 1) dapagliflozin (10mg daily) for six months (DAPA group) or 2) an orally administered, daily placebo (Control group).

The study hypothesizes:

The dapagliflozin group will have higher cardiovascular risk reduction scores than the Control Group.

The 2 groups in the trial

  • PlaceboPlacebo, for comparison
  • DapagliflozinTreatment being tested

    10 Milligram (mg) orally

    Treatment: Dapagliflozin 10mg Tab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Randomized, Placebo-controlled Trial of DAPAgliflozin for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies
Plain-language title
Tests dapagliflozin after delivery in people with high-blood-pressure pregnanciesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
4 March 2026